Every year, thousands of shareholders miss deadlines to receive settlement funds. Make sure you don’t. Sign up for case alerts.
To receive more detailed alerts provide your information below.
Request Case Alerts
Allegations
The filed complaint alleges that Acelyrin, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) izokibep, the Company's lead product candidate, was less effective in treating Hidradenitis Suppurativa than defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep’s clinical and/or commercial prospects; (iii) as a result, Acelyrin also overstated the Company’s business prospects post-initial public offering; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.